TABLE 3.
MIC50, MIC90, range, and susceptibility of isolates for all antibiotics, measured in our base cohort, excluding follow-up isolatesa (n = 29)
| Antibiotic agent | MIC50 (mg/ml) | MIC90 (mg/ml) | Range (mg/ml) | S |
I |
R |
|||
|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||||
| CLA | >16 | >16 | 0.06 to >16 | 9 | 31.0 | 0 | 0.0 | 20 | 69.0 |
| AMI | 8 | 16 | 2 to >64 | 27 | 93.1 | 1 | 3.4 | 1 | 3.4 |
| FOX | 32 | 128 | 3–128 | 3 | 10.3 | 22 | 75.9 | 4 | 13.8 |
| IMI | 16 | 32 | 4 to >64 | 2 | 6.9 | 19 | 65.5 | 8 | 27.6 |
| MXF | 8 | >8 | 2 to >8 | 0 | 0.0 | 3 | 10.3 | 26 | 89.7 |
| SXT | >8 | >8 | 0.25 to >8 | 5 | 17.2 | 0 | 0.0 | 24 | 82.8 |
| LZD | 8 | 16 | 1 to >32 | 18 | 62.1 | 9 | 31.0 | 2 | 6.9 |
| CIP | 4 | >4 | 2 to >4 | 0 | 0.0 | 3 | 10.3 | 26 | 89.7 |
| DOX | >16 | >16 | 0.25 to >16 | 1 | 3.4 | 1 | 3.4 | 27 | 93.1 |
| MIN | 16 | 16 | 1 to >8 | ||||||
| TGC | 0.5 | 0.5 | 0.25–1 | ||||||
a
S, susceptible; R, resistant; I, intermediate; CLA, clarithromycin; AMI, amikacin; FOX, cefoxitin; IMI, imipenem; MXF, moxifloxacin; SXT, trimethoprim-sulfamethoxazole; LZD, linezolid; CIP, ciprofloxacin; DOX, doxyxycline; MIN, minocycline; TGC, tigecycline; TOB, tobramycin.